Search

To conduct a comparative analysis of psychopharmacotherapy effectiveness in hypochondriac disorders of late age and to identify the optimal combinations of drugs depending on the thymopathic (hypothymic and/or anxiety) components accompanying the main hypochondriac manifestation.One hundred and eight female inpatients, aged from 50 to 88 years, with leading hypochondriac symptoms of non-delusional level were enrolled in the study. All patients were examined clinically and psychopathologically using psychometric scales: the Montgomery-Asberg Depression Rating Scale, the Hamilton Anxiety Rating Scale, the hypochondria rating scale and the UKU side-effect rating scale.Based on the psychometric assessment, the patients were divided into the following groups: group 1 - subjects with hypochondriac symptoms without accented thymopathic component (Hypochondriac disorders of late age in most cases are accompanied by depressive and/or anxiety symptoms, which must be taken into account for improvement of diagnostic effectiveness and relevant selection of therapy.Провести сравнительный анализ эффективности психофармакотерапии ипохондрических расстройств в позднем возрасте и выделить оптимальные сочетания препаратов в зависимости от тимопатического (гипотимического и/или тревожного) компонента, сопровождающего основное ипохондрическое проявление.В исследование были включены 108 пациентов женского пола в возрасте от 50 до 88 лет, проходивших стационарное лечение, с ведущей ипохондрической симптоматикой небредового уровня. Все пациенты обследовались клинико-психопатологически с применением психометрических шкал: шкалы Монтгомери—Асберг, шкалы Гамильтона, шкалы оценки ипохондрии, шкалы нежелательных явлений лекарственной терапии.На основании психометрической оценки пациенты разделены на следующие группы: 1-я группа — исследуемые с ипохондрической симптоматикой без выраженного тимопатического компонента (Ипохондрические расстройства позднего возраста в большинстве случаев сопровождаются депрессивной и/или тревожной симптоматикой, которую необходимо учитывать для повышения эффективности диагностики и своевременного подбора терапии.

Background. Improvement of control methods of treatment of mycoplasma infection in children with bronchial asthma. Methods. 52 children from 1 to 4 years old with bronchial asthma who had mycoplasma antigens in the blood were examined before treatment of mycoplasma infection, 15 patients were examined in 1,5 months after treatment. Reaction of aggregate-hemagglutination, immunofluorescence assay and the reaction of the polymerase chain reaction (PCR) were used for detection of mycoplasmas’ antigens and DNA. Results. In reaction of aggregate-hemagglutination Mycoplasma pneumoniae (Mpn) was detected in 65,4% of patients, Mycoplasma hominis (Mh) — in 32,7%, Ureaplasma urealyticum — in 50%, Mycoplasma arthritidis — in 46,2%, Mycoplasma fermentrans — in 46,2%. In more detail, we investigated Mpn and Mh. Antigens of Mpn and Mh were detected in serum significantly frequently than DNA by PCR. DNA in structure of circulating immune complexes (CIC) was detected more often than in free state. After treatment by azithromycin the number of positive tests on antigens and DNA in free state and in structure of CIC decreased. In most cases DNA found in serum of blood in free state and in structure of CIC belongs to persistent living cells of mycoplasma. Conclusion. Empowering diagnosis of mycoplasma infections in asthma in children allows to base a comprehensive approach to laboratory diagnosis, monitor treatment, predict disease course.